RAC1 and acute myeloid leukemia: Validating potent effects of RAC1 inhibitors in acute myeloid leukemia (AML), Hemsing and collaborators recently reported that primary AML cultures, and especially cases harboring a nucleophosmin 1 (NPM1) mutation, presented a good responsiveness to EHop-016 and to its precursor, NSC23766, as well as to three additional RAC1 inhibitors (ZINC69391, ITX3 and 1A-116), with IC50 in the low micromolar range of concentrations [133].